We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.36 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2015 09:19 | ...Anything is possible here. Especially with Woodford increasing to 19.1% holding this month. | someuwin | |
22/5/2015 07:50 | £15 coming soon. | blueball | |
22/5/2015 07:05 | Moving up again. | someuwin | |
21/5/2015 14:51 | Stock tightly held. All buys are pushing it up. | someuwin | |
21/5/2015 11:28 | £10+ today | someuwin | |
21/5/2015 10:23 | I am convinced DDDD is in the process of being bought out. Very soon the buyer will come out with a full offer - imo. At that point the spotlight will fall on OPTI as the only other microbiome player on the london market. | someuwin | |
20/5/2015 06:11 | 20 May 2015 4D pharma plc (the "Company" or "4D") Research Update on Clinical Development 4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on its Clinical Development Programmes. The Company currently has two programmes progressing towards the clinic, Blautix, for the treatment of Irritable Bowel Syndrome ("IBS"), and Thetanix, for the treatment of Paediatric Crohn's Disease. The Board of the Company is pleased to report that a dossier for Blautix has been submitted to Swissmedic (Swiss Agency for Therapeutic Products) and the EKNZ (Swiss ethics committee) in relation to a first in man study to be carried out in healthy volunteers and individuals exhibiting symptoms of IBS. Thetanix also continues to progress towards a first in man study, to be carried out in Paediatric Crohn's patients. Following a development programme to further optimise the Thetanix drug product, it is now anticipated that this trial will commence in H2 2015. Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented "4D is at the forefront of the development of live biotherapeutics, a new class of drug designed to treat the underlying causes of disease rather than just the symptoms. A critical component of making live biotherapeutics a reality is the ability to rapidly translate candidates identified in the laboratory into pharmaceutical grade products that can be administered to patients. Over the last few months we have made tremendous progress in establishing a methodology that allows us to do just that. With Blautix and Thetanix approaching the clinic, we are applying this same methodology to our pipeline of novel live biotherapeutic treatments for additional indications, such as asthma and rheumatoid arthritis, in line with our goal of developing ground breaking treatments for a wide range of important diseases". | someuwin | |
15/5/2015 10:15 | ...Still all buys. | someuwin | |
14/5/2015 10:04 | All buys so far today. Should move up again soon. | someuwin | |
13/5/2015 11:25 | I reckon 1000p a share very soon. | blueball | |
13/5/2015 10:54 | Guys also have a look at OPTI. Same sector as 4D but only valued at £26 million with commercial deals on the way.But well done with DDDD wish I'd seen it earlier. | talkingtrades | |
13/5/2015 10:52 | Woodford also bought 15% of UTW | tjbird | |
13/5/2015 10:49 | Can't get a live price for just £1k worth. This will be moving higher imo. | someuwin | |
13/5/2015 10:29 | Over £8 now. | someuwin | |
07/5/2015 06:16 | Woodford increases holding again - now 19.1%. | someuwin | |
26/4/2015 16:06 | Thanks someuwin. I have already bought into OPTI where the valuation seems far less hyped. I guess it is all about leaps of faith! | plasybryn | |
26/4/2015 16:04 | ...It's all about the new field of science treating diseases by modifying the human microbiome. (If you want a cheaper alternative look at OptiBiotix (OPTI). Same science but valued at only £30m vs. DDDD's £400m.) Both could multiply from these levels. "David Norwood, Chairman of 4D, commented that: "Our library of bacteria is extensive, putting 4D in a world leading position in being able to continue to mine for therapeutics that could have a curative effect in a variety of important diseases with significant unmet needs. The ability of the MicroRx platform to rationally select bacteria from this library and demonstrate therapeutically relevant effects in models of disease in a matter of months is extraordinary. This is not only a significant step forward for 4D, but also the area of live biotherapeutics in general, demonstrating that the microbiome potentially has a significant role to play in disease and its treatment." | someuwin | |
26/4/2015 15:45 | I don't understand this stock. The Market Cap. is enormous. What makes it so valuable. Is it all on a promise? | plasybryn | |
22/4/2015 14:04 | Woodford adds another million DDDD shares taking him to 18.7%. | someuwin | |
14/4/2015 18:41 | £14million cash in the bank and, maybe, good prospects | illtud | |
14/4/2015 17:17 | amazing 1/2 bil pound cap no profit | tom111 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions